Cecelia Bellcross1, April Hermstad2, Christine Tallo3, Christine Stanislaw3. 1. Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA. cecelia.a.bellcross@emory.edu. 2. Rollins School of Public Health, Emory University, Atlanta, GA, USA. 3. Department of Human Genetics, Emory Healthcare, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Abstract
PURPOSE: Despite increased awareness of hereditary breast and ovarian cancer among clinicians and the public, many BRCA1/2 mutation carriers remain unaware of their risk status. The Breast Cancer Genetics Referral Screening Tool (B-RST™) was created and validated to easily identify individuals at increased risk for hereditary breast and ovarian cancer for referral to cancer genetics services. The purpose of this study was to revise B-RST™ to maximize sensitivity against BRCA1/2 mutation status. METHODS: We analyzed pedigrees of 277 individuals who had undergone BRCA1/2 testing to determine modifications to the B-RST™ 2.0 algorithm that would maximize sensitivity for mutations, while maintaining simplicity. We used McNemar's chi-square test to compare validation measures between the revised version (3.0) and the 2.0 version. RESULTS: Algorithmic changes made to B-RST™ 2.0 increased the sensitivity against BRCA1/2 mutation analysis from 71.1 to 94.0% (P < 0.0001). While specificity decreased, all screen-positive individuals were appropriate for cancer genetics referral, the primary purpose of the tool. CONCLUSION: Despite calls for BRCA1/2 population screening, there remains a critical need to identify those most at risk who should receive cancer genetics services. B-RST™ version 3.0 demonstrates high sensitivity for BRCA1/2 mutations, yet remains a simple and quick screening tool for at-risk individuals.
PURPOSE: Despite increased awareness of hereditary breast and ovarian cancer among clinicians and the public, many BRCA1/2 mutation carriers remain unaware of their risk status. The Breast Cancer Genetics Referral Screening Tool (B-RST™) was created and validated to easily identify individuals at increased risk for hereditary breast and ovarian cancer for referral to cancer genetics services. The purpose of this study was to revise B-RST™ to maximize sensitivity against BRCA1/2 mutation status. METHODS: We analyzed pedigrees of 277 individuals who had undergone BRCA1/2 testing to determine modifications to the B-RST™ 2.0 algorithm that would maximize sensitivity for mutations, while maintaining simplicity. We used McNemar's chi-square test to compare validation measures between the revised version (3.0) and the 2.0 version. RESULTS: Algorithmic changes made to B-RST™ 2.0 increased the sensitivity against BRCA1/2 mutation analysis from 71.1 to 94.0% (P < 0.0001). While specificity decreased, all screen-positive individuals were appropriate for cancer genetics referral, the primary purpose of the tool. CONCLUSION: Despite calls for BRCA1/2 population screening, there remains a critical need to identify those most at risk who should receive cancer genetics services. B-RST™ version 3.0 demonstrates high sensitivity for BRCA1/2 mutations, yet remains a simple and quick screening tool for at-risk individuals.
Authors: Nangel M Lindberg; Amanda M Gutierrez; Kathleen F Mittendorf; Michelle A Ramos; Beatriz Anguiano; Frank Angelo; Galen Joseph Journal: Per Med Date: 2021-08-27 Impact factor: 2.119
Authors: Leslie Riddle; Laura M Amendola; Marian J Gilmore; Claudia Guerra; Barbara Biesecker; Tia L Kauffman; Katherine Anderson; Alan F Rope; Michael C Leo; Mikaella Caruncho; Gail P Jarvik; Benjamin Wilfond; Katrina A B Goddard; Galen Joseph Journal: Patient Educ Couns Date: 2020-12-23
Authors: Kathleen F Mittendorf; Tia L Kauffman; Laura M Amendola; Katherine P Anderson; Barbara B Biesecker; Michael O Dorschner; Devan M Duenas; Donna J Eubanks; Heather Spencer Feigelson; Marian J Gilmore; Jessica Ezzell Hunter; Galen Joseph; Stephanie A Kraft; Sandra Soo Jin Lee; Michael C Leo; Elizabeth G Liles; Nangel M Lindberg; Kristin R Muessig; Sonia Okuyama; Kathryn M Porter; Leslie S Riddle; Bradley A Rolf; Alan F Rope; Jamilyn M Zepp; Gail P Jarvik; Benjamin S Wilfond; Katrina A B Goddard Journal: Contemp Clin Trials Date: 2021-05-11 Impact factor: 2.261
Authors: Kristin R Muessig; Jamilyn M Zepp; Erin Keast; Elizabeth E Shuster; Ana A Reyes; Briana Arnold; Chalinya Ingphakorn; Marian J Gilmore; Tia L Kauffman; Jessica Ezzell Hunter; Sarah Knerr; Heather S Feigelson; Katrina A B Goddard Journal: Hered Cancer Clin Pract Date: 2022-02-10 Impact factor: 2.857
Authors: Stephanie A Kraft; Erin Rothwell; Seema K Shah; Devan M Duenas; Hannah Lewis; Kristin Muessig; Douglas J Opel; Katrina A B Goddard; Benjamin S Wilfond Journal: J Med Ethics Date: 2020-10-06 Impact factor: 2.903
Authors: Stephanie A Kraft; Kathryn M Porter; Devan M Duenas; Claudia Guerra; Galen Joseph; Sandra Soo-Jin Lee; Kelly J Shipman; Jake Allen; Donna Eubanks; Tia L Kauffman; Nangel M Lindberg; Katherine Anderson; Jamilyn M Zepp; Marian J Gilmore; Kathleen F Mittendorf; Elizabeth Shuster; Kristin R Muessig; Briana Arnold; Katrina A B Goddard; Benjamin S Wilfond Journal: AJOB Empir Bioeth Date: 2020-09-26
Authors: Bradley A Rolf; Jennifer L Schneider; Laura M Amendola; James V Davis; Kathleen F Mittendorf; Mark A Schmidt; Gail P Jarvik; Benjamin S Wilfond; Katrina A B Goddard; Jessica Ezzell Hunter Journal: J Genet Couns Date: 2021-07-23 Impact factor: 2.537
Authors: Xuan Li; Ryan M Kahn; Noelani Wing; Zhen Ni Zhou; Andreas Ian Lackner; Hannah Krinsky; Nora Badiner; Rhea Fogla; Isabel Wolfe; Hannah Bergeron; Becky Baltich Nelson; Charlene Thomas; Paul J Christos; Ravi N Sharaf; Evelyn Cantillo; Kevin Holcomb; Eloise Chapman-Davis; Melissa K Frey Journal: JCO Clin Cancer Inform Date: 2021-06
Authors: Kathleen F Mittendorf; Chinedu Ukaegbu; Marian J Gilmore; Nangel M Lindberg; Tia L Kauffman; Donna J Eubanks; Elizabeth Shuster; Jake Allen; Carmit McMullen; Heather Spencer Feigelson; Katherine P Anderson; Michael C Leo; Jessica Ezzell Hunter; Sonia Okuyama Sasaki; Jamilyn M Zepp; Sapna Syngal; Benjamin S Wilfond; Katrina A B Goddard Journal: Fam Cancer Date: 2021-03-23 Impact factor: 2.375